Radiation therapy with curative intention in men with de novo metastatic prostate carcinoma: shoot ‘em all!

BACKGROUND: About 5% of prostate cancer cases are metastatic at diagnoses. Radiotherapy of both primary tumor and secondary lesions can be, in addition to systemic treatments, a radical alternative for selected patients. MATERIALS AND METHODS: Patients with de novo prostate carcinoma with bone or lymph node metastases were retrospectively reviewed. All patients received moderate hypofractionated IMRT/VMAT up to 63 Gy in 21 daily fractions of 3 Gy to prostate and metastases with neoadjuvant and concurrent androgen deprivation therapy (ADT). According to known advances some patients also received abiraterone, enzalutamide, or docetaxel. RESULTS: Between 2015–2020, we attended 26 prostate cancer patients (median age 69.5 years, range 52–84) with simultaneous oligometastases [mean 2.1 metastases, median 1.5 metastases (range 1–6)]. Eighteen patients (69%) presented lymph node metastases, 4 (15.5%) bone metastases and 4 (15.5%) both lymph node and bone metastases. With a median follow-up of 15.5 months (range 3–65 months), 16 patients (62%) are alive and tumor free while 10 (38%) are alive with tumor. Four patients (17%) developed tumor progression, out of irradiated area in all cases, with a median time to progression of 43.5 months (range 27–56 months). Actuarial progression-free survival (PFS) rates at 12 and 24 months were 94.1% and 84.7%, respectively. No grade > 2 acute or late complications were recorded. CONCLUSIONS: Simultaneous directed radical hypofractionated radiation therapy for prostate and metastases is feasible, well tolerated and achieves an acceptable PFS rate. However, further studies with longer follow-up are necessary to definitively address these observations

Theoretical description of the magnetic properties of μ3-hydroxo bridged trinuclear copper(II) complexes

Artículo de publicación ISIA theoretical study of the magnetic properties, using density functional theory, of a family of trinuclear μ3-OH copper(II) complexes reported in the literature is presented. The reported X-ray crystal structures of [Cu3(μ3-OH)(aat)3(H2O)3](NO3)2·H2O (HUKDUM), where aat: 3-acetylamine-1,2,4-triazole; [Cu3(μ3-OH)(aaat)3(H2- SO4)(HSO4)(H2O)] (HUKDOG), where aaat: 3- acetylamine-5-amine-1,2,4-triazole; [Cu3(μ3-OH)(PhPyCNO) 3(tchlphac)2] (HOHQUR), where PhPyCNO: phenyl 2-pyridyl-ketoxime and tchlphac: acid 2,4,5-trichlorophenoxyacetic; [Cu3(μ3-OH)(PhPyCNO)3(NO3)2(CH3OH)] (ILEGEM); [Cu3(μ3-OH)(pz)3(Hpz)3(ClO4)2] (QOPJIP), where Hpz0pyrazole; [Cu3(μ3-OH)(pz)3(Hpz)(Me3CCOO) 2] 2Me3CCOOH (DEFSEN) and [Cu3 (μ3-OH)(8- amino-4-methyl-5-azaoct-3-en-2-one)3][CuI3] (RITXUO), were used in the calculations. The magnetic exchange constants were calculated using the broken-symmetry approach. The calculated J values are for HUKDUM J10 −68.6 cm−1, J20−69.9 cm−1, J30−70.4 cm−1; for HUKDOG, J10−73.5 cm−1, J20−58.9 cm−1, J30−62.1 cm−1; for HOHQUR J10−128.3 cm−1, J20−134.1 cm−1, J30−120.4 cm−1; for ILEGEM J10−151.6 cm−1, J20−173.9 cm−1, J30−186.9 cm−1; for QOPJIP J10−118.3 cm−1, J20−106.0 cm−1, J30 −120.6 cm−1; for DEFSEN J10−74.9 cm−1, J20−64.0 cm−1, J30−57.7 cm−1 and for RITXUO J10−10.9 cm−1, J20 +14.3 cm−1, J30−35.4 cm−1. The Kahn-Briat model was used to correlate the calculated magnetic properties with the overlap of the magnetic orbitals. Spin density surfaces show that the delocalization mechanism is predominant in all the studied compounds

Quality of life improvement in patients with bone metastases undergoing palliative radiotherapy

Background: The aim of the study was to analyze the impact of palliative radiotherapy on quality of life (QoL) in patients with symptomatic bone metastases. Materials and methods: We present the results from a prospective multicentric study including 128 patients who provided pre- and post-radiotherapy (one month after treatment) brief pain inventory (BPI) assessments. Worst pain was recorded using the BPI (range: 0–10). Pain response was described according to the International Bone Metastases Consensus on palliative radiation. Regarding QoL, for each pre- and post-radiation BPI-questionnaire, scores from the interference domains were summed and averaged to obtain an overall interference score. Results: There was a significant correlation between radiation treatment response and improvement in all functional interference domains except sleeping. Patients > 75 years old presented a significantly higher improvement in general activity, mood and relationships with others compared to patients ≤ 75 years old. Patients presenting a baseline pain score ≥ 8 showed a higher improvement in the general activity item (p = 0.049). There was no statistically significant association between pretreatment ECOG, chemotherapy, primary tumor location and radiation schedule with any of the functional interference items. Conclusions: Patients who report pain relief after palliative radiotherapy also present a better quality of life including physical and psychosocial aspects